Viromed Medical AG · ISIN: DE000A3MQR65 · EQS - adhoc news

Viromed Medical AG plans to acquire all shares of ActivCell Group AG by way of a capital increase against contribution in kind with exclusion of subscription rights

Viromed Medical AG plans to acquire all shares in ActivCell Group AG by way of a capital increase against contribution in kind with exclusion of subscription rights Pinneberg, 17 September 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus strategically expand its product portfolio. To this end, the Company has today signed a term sheet with the owners of ActivCell Group AG and will immed...

BER:Q11 Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Viromed Medical AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (2357)
Short Selling (DE) (0)
Short Selling (UK) (0)
17 September 2024 03:40PM
Viromed Medical AG plans to acquire all shares of ActivCell Group AG by way of a capital increase against contribution in kind with exclusion of subscription rights
DE000A3MQR65
Viromed Medical AG plans to acquire all shares in ActivCell Group AG by way of a capital increase against contribution in kind with exclusion of subscription rights Pinneberg, 17 September 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus s...
Viromed Medical AG
About the publication
17 September 2024 03:40PM
Viromed Medical AG plans to acquire all shares of ActivCell Group AG by way of a capital increase against contribution in kind with exclusion of subscription rights
DE000A3MQR65
Viromed Medical AG plans to acquire all shares in ActivCell Group AG by way of a capital increase against contribution in kind with exclusion of subscription rights Pinneberg, 17 September 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus s...
Viromed Medical AG
About the publication
02 September 2024 10:00AM
Successful start of trading on XETRA
DE000A3MQR65
Viromed Medical AG: Successful start of trading on XETRA   Listing on leading German financial market increases liquidity and expands investor base Aiming to expand its pioneering role in the medical use of cold plasma technology Pinneberg, 2 September 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) has reached another mil...
Viromed Medical AG
About the publication
10 July 2024 07:30AM
Viromed Medical AG seeks special approval for cold plasma device for the prevention of ventilator-associated pneumonia (VAP)
DE000A3MQR65
Viromed Medical AG seeks special approval for cold plasma device for the prevention of ventilator-associated pneumonia (VAP) Targeted use of the antimicrobial effect of cold plasma beyond wound treatment Use of cold plasma could revolutionize the treatment of VAP and significantly reduce mortality Aiming for rapid special approval for own devic...
Viromed Medical AG
About the publication
05 July 2024 05:30PM
Viromed Medical GmbH and terraplasma medical GmbH terminate their cooperation with immediate effect
DE000A3MQR65
Viromed Medical AG: Viromed Medical GmbH and terraplasma medical GmbH terminate their cooperation with immediate effect Pinneberg, 5 July 2024 – Viromed Medical GmbH, a wholly owned subsidiary of Viromed Medical AG, and terraplasma medical GmbH have today terminated their business relation with immediate effect. As part of the previous cooperation...
Viromed Medical AG
About the publication
22 April 2024 04:30PM
Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care® by Viromed with significant growth potential
DE000A3MQR65
Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care® by Viromed with significant growth potential Pinneberg, 22 April 2024 – Viromed Medical AG (ISIN: DE000A3MQR65) has concluded an agreement with CORIUS Group for the exclusive use of the pioneering cold plasma therapy with Plasma Care® by V...
Viromed Medical AG
About the publication
22 April 2024 01:05PM
Viromed Medical AG concludes agreement with CORIUS Group for exclusive use of cold plasma therapy with Plasma Care® – Additional earnings contribution of EUR 0.28 to EUR 0.34 per share expected
DE000A3MQR65
Viromed Medical AG concludes agreement with CORIUS Group for exclusive use of cold plasma therapy with Plasma Care® by Viromed – Additional earnings contribution of EUR 0.28 to EUR 0.34 per share expected from 2025 onwards Pinneberg, 22 April 2024 – Viromed Medical AG (ISIN: DE000A3MQR65) has concluded an agreement with CORIUS Group for the exclusi...
Viromed Medical AG
About the publication
06 October 2023 09:05AM
Cold plasma is a quantum leap for the treatment of chronic wounds
DE000A3MQR65
  Hamburg / Munich - 06.10.2023 - For people with chronic and non-healing wounds, there is a solution: cold atmospheric plasma (KAP). As proven by a pilot study commissioned by Munich-based terraplasma medical GmbH, a company of the Hamburg-based Viromed Group, the innovative wound and skin treatment of the cold plasma technique is superior to stan...
Viromed Medical AG
About the publication
More Viromed Medical AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 2357 20th November 2024 Perbandt, Uwe DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN